Compare Ascendis Pharma A/S (ASND) vs GE Aerospace (GE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs GE Aerospace — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while GE Aerospace trades at $358.44 (market cap $374.84B). The key difference: GE Aerospace is far larger — about 21.1× Ascendis Pharma A/S's market cap, and GE Aerospace pays a 0.52% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | GE | |
|---|---|---|
Market Cap | $17.74B | $374.84B |
Sector | Health | Industrials |
52-Week High | $277.18 | $378.68 |
52-Week Low | $163.32 | $255.42 |
Enterprise Value | $18.11B | $384.14B |
Dividend Yield | — | 0.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
GE Aerospace trades at $359.27, up 0.06% with a bullish technical signal supported by strong earnings beats and robust order growth. The company demonstrates improving fundamentals with revenue growth from $38.7B to $45.9B (2024-2025) and net income margin expansion to 18.98%. Recent defense contracts and commercial engine demand fuel positive sentiment, though elevated valuation ratios (P/E 44.63, P/S 7.9) warrant caution.
Outlook remains positive with 68.6% analyst buy ratings and $399.43 consensus target offering 11% upside. Key opportunities include aerospace demand surge and defense contract wins, while risks involve high debt levels ($19.27B total debt) and rich valuations that may limit near-term gains despite strong operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About GE Aerospace
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →
